JP2016503425A - Ｔ細胞特異的代替的ｐ３８活性化経路の阻害剤および使用法 - Google Patents

Ｔ細胞特異的代替的ｐ３８活性化経路の阻害剤および使用法 Download PDF

Info

Publication number
JP2016503425A
JP2016503425A JP2015543121A JP2015543121A JP2016503425A JP 2016503425 A JP2016503425 A JP 2016503425A JP 2015543121 A JP2015543121 A JP 2015543121A JP 2015543121 A JP2015543121 A JP 2015543121A JP 2016503425 A JP2016503425 A JP 2016503425A
Authority
JP
Japan
Prior art keywords
polypeptide
cells
cell
fusion protein
gadd45α
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503425A5 (https=
Inventor
ジョナサン ディー． アシュウェル，
ジョナサン ディー． アシュウェル，
ムハンマド エス． アラム，
ムハンマド エス． アラム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2016503425A publication Critical patent/JP2016503425A/ja
Publication of JP2016503425A5 publication Critical patent/JP2016503425A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
JP2015543121A 2012-11-20 2013-11-19 Ｔ細胞特異的代替的ｐ３８活性化経路の阻害剤および使用法 Pending JP2016503425A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261728368P 2012-11-20 2012-11-20
US61/728,368 2012-11-20
US201361774066P 2013-03-07 2013-03-07
US61/774,066 2013-03-07
PCT/US2013/070813 WO2014081728A1 (en) 2012-11-20 2013-11-19 Inhibitors of the t cell-specific alternative p38 activation pathway and methods of use

Publications (2)

Publication Number Publication Date
JP2016503425A true JP2016503425A (ja) 2016-02-04
JP2016503425A5 JP2016503425A5 (https=) 2016-11-10

Family

ID=50776497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543121A Pending JP2016503425A (ja) 2012-11-20 2013-11-19 Ｔ細胞特異的代替的ｐ３８活性化経路の阻害剤および使用法

Country Status (6)

Country Link
US (1) US9359418B2 (https=)
EP (1) EP2922865A4 (https=)
JP (1) JP2016503425A (https=)
AU (1) AU2013348112A1 (https=)
CA (1) CA2891425A1 (https=)
WO (1) WO2014081728A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111206098B (zh) * 2020-02-10 2023-02-21 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） p38γ在制备胰腺癌预后诊断试剂中的应用
CN119236082A (zh) * 2024-10-16 2025-01-03 遵义医科大学附属医院 Mapk4激动剂在制备类风湿性关节炎药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077983A2 (en) * 2004-02-05 2005-08-25 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Modulating p38 kinase activity
US20060088888A1 (en) * 1999-03-25 2006-04-27 The Government of the United States, as represented by the Secretary of the Department of Methods of identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity
JP2010522155A (ja) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド Ｐ３８阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354898B2 (en) * 2001-10-02 2008-04-08 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK
AU2004203373A1 (en) 2003-07-25 2005-02-10 University Of Chicago Identification of novel factors that block programmed cell death or apoptosis by targeting JNK

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088888A1 (en) * 1999-03-25 2006-04-27 The Government of the United States, as represented by the Secretary of the Department of Methods of identifying inhibitors of GADD45 polypeptide activity, and inhibitors of such activity
WO2005077983A2 (en) * 2004-02-05 2005-08-25 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Modulating p38 kinase activity
JP2010522155A (ja) * 2007-03-20 2010-07-01 カディラ ファーマシューティカルズ リミテッド Ｐ３８阻害剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23(11):3859-3871, JPN6016043762, ISSN: 0003439771 *
蛋白質核酸酵素, 2002, 47(11)1415-1419, JPN6016043764, ISSN: 0003439772 *

Also Published As

Publication number Publication date
EP2922865A4 (en) 2016-06-29
US9359418B2 (en) 2016-06-07
US20160083442A1 (en) 2016-03-24
EP2922865A1 (en) 2015-09-30
WO2014081728A1 (en) 2014-05-30
WO2014081728A8 (en) 2015-06-18
AU2013348112A1 (en) 2015-05-28
CA2891425A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
Gorman et al. Regulation of T cell responses by the receptor molecule Tim-3
EP1931375B1 (en) Chemo-immunotherapy method
JP7511242B2 (ja) 自己免疫関連疾患を治療するための治療用ペプチドおよび方法
WO2014055413A2 (en) A method of providing cellular therapy using modified natural killer cells or t lymphocytes
EP3185885B1 (en) Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
JP2019535292A (ja) シグナル伝達改変タンパク質
US20210369825A1 (en) Cd40 and cd40l combo in an adv vaccine vehicle
KR20220162853A (ko) 면역요법의 방법
Lu et al. Unique features of pancreatic-resident regulatory T cells in autoimmune type 1 diabetes
KR102033215B1 (ko) 건선 유발 동물 모델 및 이의 용도
Li et al. The role of T cells in the development of Henoch-Schonlein purpura
US9359418B2 (en) Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
CN114828890A (zh) 使用了干细胞迁移剂的糖尿病治疗
JP6442403B2 (ja) 代謝調節のための方法および組成物
CN117750976A (zh) 用于糖尿病以及并发病的新型治疗、诊断和检测的方法以及制剂
TWI359271B (en) Pharmaceutical composition for insulin resistance
EP2931293B1 (en) Compositions and methods for regulating erythropoiesis
US9395368B2 (en) Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors
KR20170020696A (ko) Fgf12를 이용한 혈관 평활근세포 증식성 질환의 진단, 예방 또는 치료용 조성물
CN113398270B (zh) 一种治疗骨巨细胞瘤的方法
US20200225249A1 (en) Compositions and methods for the diagnosis and treatment of diseases of the liver
US20190309044A1 (en) Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
Lau Remodelling of the immune landscape and its effect of tumour immunity in a model of IFNy-insensitive murine melanoma
Zhang et al. Vam6 upregulated by lactic acid inhibits anti-tumor effects of intratumoral iNKT cells via modulating AMPK/mTOR pathways
HK40073547A (en) Therapy for diabetes using stem cell migration agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160923

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160923

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20161018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161114

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170620